Completed PHASE1 INTERVENTIONAL 4-arm NCT02062203

Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers

A Phase 1, Single-Center, Partially Double-Blinded, Active and Placebo Controlled, Randomized 4-Way Crossover Study to Evaluate the Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers

Sponsor: Akebia Therapeutics

Conditions Healthy Volunteers

Interventions AKB-6548 (supratherapeutic dose) AKB-6548 (therapeutic dose) Moxifloxacin Placebo

Updated 8 times since 2017 Last updated: Nov 10, 2018 Started: Jan 31, 2014 Primary completion: Apr 30, 2014 Completion: Apr 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Healthy Volunteers and is currently completed. Akebia Therapeutics leads this study, which shows 8 recorded versions since 2014 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Dec 2018 — Jan 2021 [monthly]

Completed PHASE1
Oct 2018 — Dec 2018 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

Jun 2018 — Oct 2018 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jan 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Akebia Therapeutics

Data source: Akebia Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Evansville, United States